This inventor holds 9 USPTO granted patents and 1 EPO patent. Top assignees: Dana-Farber-Cancer Institute Inc., Washington University. Active years: 2006-2019.
Location History:
- Roslindale, MA (US) (2006)
- Walpole, MA (US) (2008 - 2019)
Company Filing History:
9 out of 1,266 
1 out of 1,379 
Years Active: 2006-2019
Title: The Innovative Contributions of Andrew L Kung
Introduction
Andrew L Kung is a prominent inventor based in Roslindale, MA (US). He has made significant contributions to the field of cancer research, holding a total of 9 patents. His work focuses on improving patient outcomes through innovative methods of cancer prognosis.
Latest Patents
One of Kung's latest patents is titled "NOL3 is a predictor of patient outcome." This invention features a method for determining the prognosis for survival of a cancer patient. It includes methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient. The process involves comparing the level of NOL3 expression in the sample to a reference level of NOL3 expression. A higher level of NOL3 relative to the reference level correlates with decreased survival of the patient. Conversely, an equivalent or lower level of NOL3 relative to the reference level correlates with increased survival of the patient.
Career Highlights
Throughout his career, Andrew L Kung has worked with esteemed organizations such as Dana-Farber Cancer Institute Inc. and Washington University. His experience in these institutions has allowed him to collaborate with leading experts in the field of cancer research.
Collaborations
Some of his notable coworkers include David M Livingston and David Ziegler. Their collaborative efforts have contributed to advancing research and innovation in cancer prognosis.
Conclusion
Andrew L Kung's innovative work in cancer research exemplifies the impact of inventions on patient outcomes. His contributions continue to shape the future of medical science and improve the lives of many patients.